Navigation Links
BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments
Date:3/27/2008

Oncolix, Inc. Selects CryoStor(TM) for Cryopreservation of Cell-Based

Melanoma Therapy

BOTHELL, Wash., March 27 /PRNewswire-FirstCall/ -- BioLife Solutions Inc. (OTC Bulletin Board: BLFS), a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues, and organs, today provided updated information on the adoption of its products in the cellular therapy and cord blood banking market segments.

BioLife announced that Oncolix, Inc., a biopharmaceutical company based in Greenville, South Carolina, is developing a potential lifesaving treatment for stage IV melanoma and has adopted CryoStor for the cryopreservation of the Company's proprietary dendritic cell-based cancer therapy. Michael Redman, President and CEO of Oncolix, commented on the selection of CryoStor for the company's novel treatment for stage IV melanoma by stating, "We evaluated other commercial cryopreservation media as well as an in-house formulation and found that CryoStor clearly offered post-preservation improvement in cellular yield and function without the use of human serum. Our 25-patient phase II clinical trial will commence within a few weeks so we're quite pleased that this variable in our development process has been locked down."

BioLife Chairman and CEO Mike Rice also commented on the use of CryoStor for the cryopreservation of umbilical cord blood: "The worldwide cord blood banking market is experiencing significant growth. We are currently supporting evaluations of CryoStor at several of the largest cord blood banks in the US, Europe, and Asia, and are optimistic that the results of these evaluations will mimic earlier published data about the advantages CryoStor and could lead to further product adoption in this key market."

Rice then remarked on the growing adoption of BioLife products in two strategic market segments: "We're happy to report that we have gained nu
'/>"/>

SOURCE BioLife Solutions Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Ken Sperling to Lead CIGNA HealthCare Retiree Solutions Unit
2. Frances Decker Named Mid-Atlantic Region Sales Executive for AllOne Health Management Solutions
3. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
4. SXC Health Solutions to present at the 2007 UBS Global Life Sciences Conference
5. The Village Company Unveils Natural Bath and Body Solutions for Everyday Ailments
6. RESolutions Rapid Enrollment Solutions, LLC Mobilizes Team of Regional Recruitment Specialists(TM)
7. MedQuist and MedAssets Sign Multi-Year Contract for Clinical Documentation Workflow Solutions
8. Ingenious Med Forms Multiple Billing Company Partnerships to Market Inpatient Practice Management Solutions
9. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
10. SYMX Builds on Top of New Microsoft Technologies to Offer Hospitals Real-Time Business and Patient Safety Solutions Using RFID Data
11. InfoLogix Signs Largest International Deal to Date with Healthcare Solutions Agreement in United Arab Emirates

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...rsity researchers, from the School of Medicine,s D...ic pathways by which products of lipid peroxidatio..., are metabolized. The pathways were identified by... analysis. The findings shed new light on the mech...butyrate, also known as "the date rape drug." The ...
(Date:12/4/2009)...ure done immediately or 3 weeks later, study shows...Timing of surgical repair or reconstruction of mul...t outcome, a new study has found. , Multiple-li...slocations that can occur in high-impact car crash...rm surgery to repair these injuries hasn,t been de...
(Date:12/4/2009)...r Applauds Historic Effort but Points out Potentia...n Final Health Care Reform ,, NEW YORK, Dec. ...rnal of Medicine today published a Perspective o...hored by Irwin Redlener, M.D., president, Children...isaster Preparedness and Professor of Clinical Pop...
(Date:12/4/2009)...through hookah, research shows , , FRIDA...afer than cigarettes for smoking tobacco, research...oke tobacco with a water pipe inhale carbon monoxi... disease and nicotine addiction. , The study in...bacco using a water pipe and a single cigarette. A...
(Date:12/4/2009)... Dec. 4 When the spread ...epartment of Health Services needed to get more in...fore. Join Sonic Foundry, Inc. (Nasdaq: SOFO ),...sting and knowledge management, for a live webinar... of Health Services, will share how in-house webca...
Breaking Medicine News(10 mins):Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2Health News:Water Pipes No Safer Than Cigarettes 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 3
...s Corp. (Nasdaq:,HMSY) today announced that it wil...onference, which will be held January 7-10, 2008 a...: http://www.newscom.com/cgi-bin/prnh/20030304/NY...ast of the Company,s presentation can be accessed ...
...nix,Pharmaceuticals, Inc. (Nasdaq: IDIX ) announc...porate overview, including an update of the compan..., at the upcoming JP Morgan 26th,Annual Healthcare...entation can be accessed,under "Calendar of Events...
...am for Lead Product, MENLO PARK, Calif., Dec. 20 ...t it has completed a private placement financing,r...opment of the company,s,novel antiplatelet therapy...on,from Prospect Venture Partners, Ridgeback Capit...
...-Opportunities program of Agriculture and ..., ON, Dec. 20 /PRNewswire-FirstCall/ - Bioniche Li...hnology-driven Canadian,biopharmaceutical company,... Ontario. The $5 million repayable,contribution ha...
..., 2007 Wiley-Blackwell, the scientific, technical...n Wiley & Sons, Inc (NYSE: JWa), (NYSE: JWb), and ...anisation dedicated to improving healthcare decisi...World Banks list of low-income economies (countrie...
...dds, study found , THURSDAY, Dec. 20 (HealthDay Ne...cy can boost a child,s risk of developing allergie...nska Institute, Stockholm, analyzed questionnaires...s, 2 years and 4 years. In addition, the researche...
Other Medicine News:Health News:Cogentus Pharmaceuticals Completes $62.5 Million Private Financing 2Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 2Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 3Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 4Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 5Health News:Low-income countries now have free, one-click access to Cochrane Library 2Health News:Parents' Smoking Boosts Child's Allergy Risk 2
(Date:12/4/2009)..., ANNAPOLIS, Md., Dec. 4 /PRNewswire-FirstCall/ -...se company developing medical countermeasures agai...ay the presentation of new data from the Company,s...zed recombinant Protective Antigen (rPA) based ant...er 16 months at various temperatures up to and inc...
(Date:12/4/2009)..., SAN DIEGO, Calif., Dec. 4 Sunev...ce company, today announced the appointment of Phi...fficer. In this role, Mr. Ranker will lead all Su...s including finance, accounting, IT, IR, administr...the Company,s senior management team. ,, "One ...
(Date:12/4/2009)..., BETHESDA, Md., Dec. 4 Drs. Neal ...prostate-specific antigen (PSA) recurrence from th...iochemical recurrence rate in a Phase III pivotal ...ection) or monthly leuprolide in prostate cancer p...ate cancer patients who received FIRMAGON 240/80 m...
Breaking Medicine Technology:PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Middle Age Heart Risk Factors Shorten Mens Lives 57598 1Middle Age Heart Risk Factors Shorten Mens Lives 57598 2Middle Age Heart Risk Factors Shorten Mens Lives 57598 3Northwest Hospital 26 Medical Center to Join UW Medicine 57596 1Northwest Hospital 26 Medical Center to Join UW Medicine 57596 2Northwest Hospital 26 Medical Center to Join UW Medicine 57596 3U S Chamber 3A Medical Liability Reform Must Have Teeth to be Effective 57594 1
...r and Imaging Study) Results Demonstrate ...SAN DIEGO, Calif., Sept. 2 Volcano,Corporation (N...nufacturer of,intravascular ultrasound (IVUS) and ...oday the use of its VH(R) IVUS (Virtual Histology ...d Biomarker and Imaging Study). In,the study, Volc...
...sty and Stenting Safe and Effective in Patients ...t Surgery, WASHINGTON, Sept. 1 Data announced to...atients with very complex coronary,artery disease ...nd,drug-eluting stents rather than open-heart surg...hy and Interventions (SCAI). The one-year results,...
Other Medicine Technology:Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 2Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 3Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 4SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 2SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 3
Endoscope
Neuroview 1.2 mm Neuroendoscopes
...atch is a synthetic absorbable implant for the bri...s. Ethisorb Dura Patch is pliable, regardless of b...e, care must be taken, while implanting, to ensure...de is oriented towards the cortex or the spinal co...
IDS-300 Electrosurgical Generator
Medicine Products: